Compare · DRTS vs WST
DRTS vs WST
Side-by-side comparison of Alpha Tau Medical Ltd. (DRTS) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DRTS and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $22.22B, about 27.0x DRTS ($822.9M).
- Over the past year, DRTS is up 198.1% and WST is up 42.4% - DRTS leads by 155.7 points.
- DRTS has been more active in the news (10 items in the past 4 weeks vs 4 for WST).
- WST has more recent analyst coverage (16 ratings vs 7 for DRTS).
- Company
- Alpha Tau Medical Ltd.
- West Pharmaceutical Services Inc.
- Price
- $9.33-0.32%
- $318.69+1.36%
- Market cap
- $822.9M
- $22.22B
- 1M return
- +18.93%
- -1.02%
- 1Y return
- +198.08%
- +42.38%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 10
- 4
- Recent ratings
- 7
- 16
Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest DRTS
- Chief Financial Officer Levy Raphi sold $352,115 worth of Ordinary Shares (32,500 units at $10.83), decreasing direct ownership by 18% to 147,680 units (SEC Form 4)
- SEC Form 6-K filed by Alpha Tau Medical Ltd.
- Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients
- SEC Form 6-K filed by Alpha Tau Medical Ltd.
- Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting
- Barclays initiated coverage on Alpha Tau with a new price target
- SEC Form 6-K filed by Alpha Tau Medical Ltd.
- SEC Form 6-K filed by Alpha Tau Medical Ltd.
- Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update
- Alpha Tau to Participate in May Investor Conferences
Latest WST
- Wolfe Research resumed coverage on West Pharm with a new price target
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- West Appoints Michel Lagarde to be President and Chief Executive Officer
- Amendment: West Pharmaceutical Services Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SVP, Proprietary Segment Campbell Shane Alden covered exercise/tax liability with 219 shares and converted options into 770 shares, increasing direct ownership by 881% to 613 units (SEC Form 4)
- SEC Form SD filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Director Pucci Paolo was granted 791 shares, increasing direct ownership by 7% to 11,854 units (SEC Form 4)
- Director Michels Douglas A was granted 791 shares, increasing direct ownership by 2% to 46,496 units (SEC Form 4)
- Director Lockhart Stephen H was granted 791 shares, increasing direct ownership by 29% to 3,523 units (SEC Form 4)